07th week of 2015 patent applcation highlights part 40 |
Patent application number | Title | Published |
20150044183 | STEM CELL BASED ANTI-CANCER COMPOSITIONS AND METHODS - The present invention provides compositions and methods for target radiotherapeutic treatment of cancer. Freshly isolated or culture expanded ELA stem cells are loaded with at least one of a diagnostic agent and a therapeutic agent, and the stem cells are then introduced into a subject. The loaded ELA stem cells migrate to location of cancer and form the basis both of diagnostic imaging and of directed Neutron Capture Therapy. Treatment of a subject may include ELA stem cell-based NCT radiotherapy as an adjunct to traditional therapies. An ELA stem cell-based diagnostic preparation can be used directly, or as a further addition to current imaging agents and methods. | 2015-02-12 |
20150044184 | SIRT1 INHIBITORS AND STEM CELL REJUVENATION - Provided herein are, inter alia, methods and compositions for treating or preventing diseases using SIRT1 inhibitors. The methods provided herein are particularly useful for treating or preventing age-related hematological diseases as well as cancerous hematological diseases. Further provided herein are hematopoietic cells useful for treating or preventing hematological diseases. | 2015-02-12 |
20150044185 | Bone Augmentation Utilizing Muscle-Derived Progenitor Compositions in Biocompatible Matrix, and Treatments Thereof - The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment non-soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of non-soft tissue (e.g. bone) when combined with a biocompatible matrix, preferably SIS. The invention further provides methods of using compositions comprising muscle-derived progenitor cells with a biocompatible matrix for the augmentation and bulking of mammalian, including human, bone tissues in the treatment of various functional conditions, including osteoporosis, Paget's Disease, osteogenesis imperfecta, bone fracture, osteomalacia, decrease in bone trabecular strength, decrease in bone cortical strength and decrease in bone density with old age. | 2015-02-12 |
20150044186 | REPAIR AND/OR RECONSTITUTION OF INVERTEBRAL DISCS - This invention relates to a method for repair and reconstitution of invertebral discs in a subject which involves administration of STRO-1 | 2015-02-12 |
20150044187 | Brain-Specific Enhancers for Cell-Based Therapy - Herein are described a set of novel specific human enhancers for specific forebrain cell types used to study and select for human neural progenitor cells. This approach enables the ability to generate interneurons from human ES, iPS and iN cells, making them available for human transplantation and for molecular/cellular analyses. These approaches are also directly applicable to generating other neuronal cell types, such as cortical and striatal projection neurons, which have implications for many human diseases. | 2015-02-12 |
20150044188 | ANTIVIRAL METHODS AND COMPOSITIONS COMPRISING PROBIOTIC BACTERIAL MOLECULES - Molecules secreted or derived from probiotic bacteria are provided for use in compositions and methods for the treatment and/or prevention of infection by pathogenic viruses. The isolated secreted molecules can also be used in nutritional or medical food products which provide probiotics to the gastrointestinal tract of a mammal. | 2015-02-12 |
20150044189 | HYBRID POLYMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME - Novel hybrid polymers are disclosed that have a structure represented by the following | 2015-02-12 |
20150044190 | PRODUCT AND PROCESS FOR LIQUEFACTION OF MUCUS OR SPUTUM - Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. The composition contains a protein or peptide containing a thioredoxin active-site in reduced state and optionally further contains a reducing system. | 2015-02-12 |
20150044191 | METHODS FOR IDENTIFYING A TARGET SITE OF A CAS9 NUCLEASE - Some aspects of this disclosure provide strategies, methods, and reagents for determining nuclease target site preferences and specificity of site-specific endonucleases. Some methods provided herein utilize a novel “one-cut” strategy for screening a library of concatemers comprising repeat units of candidate nuclease target sites and constant insert regions to identify library members that can been cut by a nuclease of interest via sequencing of an intact target site adjacent and identical to a cut target site. | 2015-02-12 |
20150044192 | METHODS FOR IDENTIFYING A TARGET SITE OF A CAS9 NUCLEASE - Some aspects of this disclosure provide strategies, methods, and reagents for selecting a site-specific endonuclease based on determining its target site preferences and specificity. Methods and reagents for determining target site preference and specificity are also provided. | 2015-02-12 |
20150044193 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED a-SYNUCLEIN FUNCTION - Compositions and methods are provided for treating a disorder characterized by α-synuclein dysfunction and/or altered lipid metabolism. | 2015-02-12 |
20150044194 | High Concentration Alpha-Glucosidase Compositions for the Treatment of Pompe Disease - The present application provides for compositions comprising high concentrations of acid α-glucosidase in combination with an active site-specific chaperone for the acid α-glucosidase, and methods for treating Pompe disease in a subject in need thereof, that includes a method of administering to the subject such compositions. The present application also provides methods for increasing the in vitro and in vivo stability of an acid α-glucosidase enzyme formulation. | 2015-02-12 |
20150044195 | FVIIa-sTF complexes exhibiting exosite-mediated super activity - Disclosed are disulphide-linked complexes of a soluble Tissue Factor (sTF) variant of SEQ ID NO:3 comprising the mutation G109C and a Factor VIIa variant of SEQ ID NO. 1, comprising the mutation Q64C and a mutation at position M306 that gives rise to a zymogen-like conformation in the Factor VIIa polypeptide. Said complexes may be used for the treatment of a coagulopathy. | 2015-02-12 |
20150044196 | Compositions for Inhibiting Gene Expression and Uses Thereof - The inventors have examined the means for providing more efficacious miRNA blocking compounds. The inventors have discovered new structural features that surprisingly improve the efficacy of miRNA blocking molecules. These features include the presence of multiple 3′ ends and a linker at the 5′ ends. Surprisingly, these features improve the efficacy of the gene expression blocking compounds in a manner that decreases the compound's biologic instability. Even more surprisingly, this effect has been found to be applicable to both DNA and RNA oligonucleotide-based compounds and to have application in traditional antisense and RNAi technology. | 2015-02-12 |
20150044197 | ANTIBODIES THAT SPECIFICALLY BIND TO THE EPHA2 RECEPTOR - The present disclosure relates to an antibody or an epitope-binding fragment thereof that specifically binds to an EphA2 receptor. It further relates to a conjugate comprising a cytotoxic agent which is covalently bound to the antibody and a method for preparing such a conjugate. | 2015-02-12 |
20150044198 | REDUCED-VISCOSITY CONCENTRATED PROTEIN FORMULATIONS - The present application concerns concentrated protein formulations with reduced viscosity, which are particularly suitable for subcutaneous administration. The application further concerns a method for reducing the viscosity of concentrated protein formulations. | 2015-02-12 |
20150044199 | COMPOSITIONS AND METHODS FOR TREATING TUMORS, FIBROSIS, AND PULMONARY ALVEOLAR PROTEINOSIS - The present disclosure provides pharmaceutical compositions and methods useful for modulating angiogenesis and for inhibiting metastasis, tumors, pulmonary alveolar proteinosis, and fibrosis in a mammalian tissue. Pharmaceutical compositions and methods include inhibitors of LOXL2 expression and activity, such as shRNA targeting LOXL2. | 2015-02-12 |
20150044200 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM - The present invention relates to the treatment or prevention of tinnitus. More precisely, the present invention relates to a compound modulating chloride co-transporter NKCC1 (chloride co-transporter modulator) for use in the treatment of tinnitus. In addition, the present invention concerns pharmaceutical compositions comprising such an NKCC1 chloride co-transporter modulator as an active agent, a method for the treatment or prevention of tinnitus by administering such a chloride co-transporter modulator, and a screening method for the identification and characterization of compounds capable of modulating chloride co-transporter NKCC1. | 2015-02-12 |
20150044201 | CYCLON EXPRESSION FOR THE IDENTIFICATION AND CONTROL OF CANCER CELLS - The present disclosure concerns a method for the identification of the presence or absence of cancer cells in a biological sample, more particularly a method for the identification of the susceptibility or resistance to a treatment with CD20 agonists of cancer cells in a biological sample, the methods including determining the level of expression of the gene Cyclon in the cells and comparing the level of expression to the level of expression in a non-cancer cell, wherein a level of expression higher than the level of expression in a non-cancer cell is an indication of the presence of a cancer cell, more particularly an indication of cancer cells with a resistance to treatment with antagonists. Kits for the determination of a level of expression of the Cyclon gene in a biological sample, a method for the identification of Cyclon expression antagonists, and methods for treating patients are provided. | 2015-02-12 |
20150044202 | METHODS FOR REDUCING EXACERBATION RATES OF ASTHMA USING BENRALIZUMAB - Provided herein is are methods of reducing exacerbations of asthma in an asthma patient, comprising administering to the patient an effective amount of the anti-interleukin-5 receptor (IL-5R) antibody benralizumab or an antigen-binding fragment thereof. | 2015-02-12 |
20150044203 | Methods For Increasing Forced Expiratory Volume In Asthmatics Using Benralizumab - Provided herein is are methods of increasing forced expiratory volume in one second (FEV | 2015-02-12 |
20150044204 | METHODS FOR IMPROVING ASTHMA SYMPTOMS USING BENRALIZUMAB - Provided herein are methods of improving asthma symptoms, e.g., as measured by an asthma control questionnaire, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof. | 2015-02-12 |
20150044205 | COMPOSITIONS AND METHOD FOR TREATING COMPLIMENT-ASSOCIATED CONDITIONS - The invention provides methods and compositions for treating various degenerative diseases (e.g., AMD) with a factor D inhibitor (e.g., anti-factor D antibody or antigen-binding fragment thereof). Also provided are methods of selecting or identifying patients for treatment with a factor D inhibitor. Methods include the use of prognostic and/or predictive biomarkers. | 2015-02-12 |
20150044206 | IMMUNOGLOBULIN FORMULATION AND METHOD OF PREPARATION THEREOF - A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, polysorbate 80, a buffer which inhibits polysorbate oxidation is described along with methods of making the preparation. Also described are formulations with high antibody concentrations which maintain fixed volumes and which may be used on patients of variable weight. | 2015-02-12 |
20150044207 | Clotting Factor-Fc Chimeric Proteins to Treat Hemophilia - The Invention relates to a chimeric protein comprising at least one clotting factor and at least a portion of an immunoglobulin constant region. The invention relates to a method of treating a hemostatic disorder comprising administering a therapeutically effective amount of a chimeric protein wherein the chimeric protein comprises at least one clotting factor and at least a portion of an immunoglobulin constant region. | 2015-02-12 |
20150044208 | Modified Albumin-Binding Domains and Uses Thereof to Improve Pharmacokinetics - The present invention relates to compositions and methods comprising a modified albumin-binding domain to improve the pharmacokinetic properties of therapeutic molecules. The modified peptides show reduced immunogenicity and/or proved solubility. In particular, compositions and methods for enhancing therapeutic potential of protein therapeutics are provided including linking a protein albumin-binding domain, which has been modified to reduce immunogenicity and/or improve solubility, to a therapeutic protein, including therapeutic antibodies, antibody fragments, antibody single domains and/or dimers of antibody single domains. These linked polypeptides can exhibit enhanced serum half life without exacerbated immunogenicity and/or without decreased solubility, and without substantially affecting the specific binding properties of the therapeutic protein. | 2015-02-12 |
20150044209 | SOLUBLE IGF RECEPTOR Fc FUSION PROTEINS AND USES THEREOF - There are described herein novel soluble IGF receptor Fc fusion proteins and compositions and methods of use thereof for treating angiogenesis associated disorders and malignant disease, such as cancer and metastasis, wherein the fusion proteins bind specifically to IGF-1 or IGF-2. | 2015-02-12 |
20150044210 | MODIFIED MICROBIAL TOXIN RECEPTOR FOR DELIVERING AGENTS INTO CELLS - We described a novel system of targeted cell therapy with a protein toxin, such as anthrax toxin, that has been modified to re-direct it to a desired cell target instead of its natural cell target. The system can be used for, e.g., targeted killing of undesired cells in a population of cells, such as cancer or overly active immune system cells. | 2015-02-12 |
20150044211 | COMBINATION OF A 6-OXO-1,6-DIHYDRO-PYRIDAZINE DERIVATIVE HAVING ANTI-CANCER ACTIVITY WITH OTHER ANTI-TUMOR COMPOUNDS - A pharmaceutical composition of 3-(1-{3-[5-(1-Methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof in combination with a compound selected from the group erlotinib, cetuximab, aflibercept, bevacizumab. | 2015-02-12 |
20150044212 | Antibodies Directed to GPNMB and Uses Thereof - The present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. The present invention further provides bi-specific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies. | 2015-02-12 |
20150044213 | PROTEIN SUSTAINED-RELEASE INJECTABLE FORMULATION - The present invention provides sustained-release pharmaceutical formulations for administering proteins to the eye. In particular, the invention provides formulations comprising single chain antibodies and hydrophobic polyester hexylsubstituted poly(lactic acid) (hexPLA). The invention further provides processes for the production of sustained-release pharmaceutical formulations and medical uses thereof. | 2015-02-12 |
20150044214 | BISPECIFIC, TETRAVALENT ANTIGEN BINDING PROTEINS - The present invention relates to bispecific, tetravalent antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 2015-02-12 |
20150044215 | PSEUDOMONAS AERUGINOSA PCRV BINDING SINGLE VARIABLE DOMAIN ANTIBODIES - Polypeptides are provided that are capable of significantly inhibiting andor neutralizing | 2015-02-12 |
20150044216 | BISPECIFIC ANTIBODIES - Provided are bispecific antibodies having a full-size antibody portion with two light chains and two heavy chains, wherein the two heavy chains each is fused to a single-chain variable fragment (scFv) portion. In certain embodiments, the full-size antibody has specificity to EGFR and the scFv has specificity to VEGF. | 2015-02-12 |
20150044217 | METHODS FOR THE TREATMENT OF HER2 AMPLIFIED CANCER - Described herein are methods and compositions for treating HER2-amplified cancer. The methods include administering to an individual in need thereof ibrutinib. | 2015-02-12 |
20150044218 | N-DOMAIN OF CARCINOEMBRYONIC ANTIGEN AND COMPOSITIONS, METHODS AND USES THEREOF - The present disclosure provides immunogenic compositions comprising the N-domain of carcinoembryonic antigen (CEA). These compositions are useful for inducing or enhancing an immune response, for inhibiting tumor cell growth and for treating cancer. | 2015-02-12 |
20150044219 | Combination of SEMA-4D Inhibitors and Immunomodulators to Inhibit Tumors and Metastases - Provided herein are methods for inhibiting, delaying, or reducing tumor growth and metastases of plexin-B1-expressing cancer cells in a subject, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) in combination with an effective amount of at least one other immune modulating therapy. | 2015-02-12 |
20150044220 | CO-USE OF A CLUSTERIN INHIBITOR WITH AN EGFR INHIBITOR TO TREAT CANCER - Epidermal growth factor receptor (EGFR) expression and phosphorylation is increased in cancer cells treated with anti-clusterin antibodies. Such treatment is also accompanied with the reappearance of an epithelial phenotype of the cancer cell, as determined by an increased E-cadherin expression at the surface of cancer cells. Clusterin inhibitors may thus induce reversal of the epithelial to mesenchymal phenotype and restore sensitivity of cancer cells to EGFR inhibitors. Combinations of a clusterin inhibitor and an EGFR as well as their use in treatment of cancer are thus provided herewith. | 2015-02-12 |
20150044221 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF CANCER - This invention provides an antibody targeting a cancer antigenic protein specifically expressed on the surface of cancer cells and use thereof as a therapeutic and/or preventive agent for cancer. Specifically, this invention provides an antibody or a fragment thereof which has immunological reactivity with a partial CAPRIN-1 polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 5 or an amino acid sequence having 80% or higher sequence identity to the amino acid sequence, and a pharmaceutical composition for treatment and/or prevention of cancer, comprising the antibody or fragment thereof as an active ingredient. | 2015-02-12 |
20150044222 | INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS AND USES THEREOF - The present invention encompasses type-I IFN and IFNα-induced PD marker expression profiles, kits, and methods for identifying such IFNα-induced PD marker expression profiles. The type-I IFN and IFNα-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFNα-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFNα activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFNα activity, and in diagnosing or providing a prognosis to patients having IFNα-induced disorders. | 2015-02-12 |
20150044223 | COMBINATION DRUG THERAPY FOR THE TREATMENT OF SOLID TUMORS - The present invention relates to a pharmaceutical combination that comprises an IGF1R inhibitor and an mTOR inhibitor for the treatment of cancer in a subject; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of medicament for the treatment of cancer; a kit comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and a method of treating cancer in a subject, especially a human. | 2015-02-12 |
20150044224 | MATERIALS AND METHODS FOR DIFFERENTIAL TREATMENT OF CANCER - The present invention concerns differential therapeutic treatment of cancer patients based on prognostic antigen/antibody profiles used for predicting (prognosticating) a clinical response (efficacy) and/or adverse event to an immunotherapy for treatment of a malignancy in a subject, and for treating or delaying the onset or relapse of a malignancy in a subject. | 2015-02-12 |
20150044225 | Human Anti-Human Influenza Virus Antibody - Provided is a human antibody having a neutralization activity against a human influenza virus. More specifically, provided is a human antibody which recognizes a highly conserved region in a human influenza A virus subtype H3N2 or a human influenza B virus and has a neutralization activity against the virus. The human antibody is a human anti-human influenza virus antibody, which has a neutralization activity against a human influenza A virus subtype H3N2 and binds to a hemagglutinin HA1 region of the human influenza A virus subtype H3N2, or which has a neutralization activity against a human influenza B virus, and includes, as a base sequence of a DNA encoding a variable region of the antibody, a sequence set forth in any one of SEQ ID NOS: 5 to 12. | 2015-02-12 |
20150044226 | Anti-Phospholipase D4 Antibody - A monoclonal antibody that binds to a phospholipase D4 (PLD4) protein, or a fragment containing an antigen-binding region thereof. | 2015-02-12 |
20150044227 | METHODS OF TREATMENT WITH ANGIOPOIETIN-2 ANTIBODIES - The disclosure is directed to methods and uses of antibodies or antigen-binding fragments thereof against Angiopoietin-2 (Ang-2). Specifically, the disclosure is direct to the use of anti-Ang2 antibodies or antigen-binding fragments thereof for treating ischemia. The methods disclosed are useful for reducing microvascular permeability, increasing microvascular perfusion, reducing inflammation in a tissue, and treating or ameliorating diseases associated with ischemia and/or reperfusion injury. The disclosed methods are also useful for protecting solid organ transplant tissue and treating or preventing chronic tissue transplant rejection. | 2015-02-12 |
20150044228 | METHODS TO IDENTIFY COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE AND DIFFERENTIATIVE DISORDERS - The present invention relates to the discovery, identification and characterization of nucleotide sequences that encode novel substrate-targeting subunits of ubiquitin ligases. The invention encompasses nucleotides encoding novel substrate-targeting subunits of ubiquitin ligases: FBP1, FBP2, FBP3, FBP4, FBP5, FBP6, FBP7, FBP8, FBP9, FBP10, FBP11, FBP12, FBP13, FBP14, FBP15, FBP16, FBP17, FBP18, FBP19, FBP20, FBP21, FBP22, FBP23, FBP24, and FBP25, transgenic mice, knock-out mice, host-cell expression systems and proteins encoded by the nucleotides of the novel substrate-targeting subunits. The present invention relates to screening assays that use novel and known substrate-targeting subunits of ubiquitin ligases to identify potential therapeutic agents such as small molecules, compounds or derivatives and analogues of the novel and known ubiquitin ligases which modulate activity of the novel and known ubiquitin ligases for the treatment of proliferative and differentiative disorders, such as cancer, major opportunistic infections, immune disorders, certain cardiovascular diseases, and inflammatory disorders. The invention further encompasses therapeutic protocols and pharmaceutical compositions designed to target ubiquitin ligases and their substrates for the treatment of proliferative and differentiative disorder. | 2015-02-12 |
20150044229 | METHODS RELATED TO TIM 3, A TH1-SPECIFIC CELL SURFACE MOLECULE, FOR ACTIVATING ANTIGEN PRESENTING CELLS - The present invention provides compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (APC) activation. The invention is related to discovery of functional characteristics of TIM-3, a molecule that is preferentially expressed on the surface of Th1 cells. The methods are useful for treating disorders including cancer, infectious disease, allergy, asthma, and autoimmune disease. | 2015-02-12 |
20150044230 | METHODS RELATED TO TIM 3, A TH1-SPECIFIC CELL SURFACE MOLECULE, FOR ACTIVATING ANTIGEN PRESENTING CELLS - The present invention provides compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (APC) activation. The invention is related to discovery of functional characteristics of TIM-3, a molecule that is preferentially expressed on the surface of Th1 cells. The methods are useful for treating disorders including cancer, infectious disease, allergy, asthma, and autoimmune disease. | 2015-02-12 |
20150044231 | Therapeutic Antibodies - The present invention concerns human antibodies recognising the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders. | 2015-02-12 |
20150044232 | MARKERS FOR THE RESPONSIVENESS TO ANTI-CD44 ANTIBODIES - The present invention relates to means and methods of determining whether a tumor cell or a cancer cell is responsive to an anti-CD44 antibody or to an antigen binding fragment thereof. The method comprises the determination of the major CD44 isoform in a sample, wherein if the major CD44 isoform is CD44s, the tumor cell or cancer cell is responsive to said anti-CD44 antibody. Also means and methods of treating a cancer patient that has been determined to respond to an anti-CD44 antibody are subject of the present invention. | 2015-02-12 |
20150044233 | GANGLIOSIDE GD2 AS A MARKER AND TARGET ON CANCER STEM CELLS - Methods for determining the presence of cancer stem cells by detecting GD2 expression. Also provided are methods for reducing proliferation of cancer stem cells by contacting the cells with a GD2 targeting agent, such as an anti-GD2 antibody or a GD3 synthase inhibitor. GD3 synthase inhibitor compounds are also provided. | 2015-02-12 |
20150044234 | MENAINV AND CANCER INVASION AND METASTASIS - Methods and compositions are provided for diagnosing or inhibiting invasion or metastasis of a cancer in a subject based on Mena | 2015-02-12 |
20150044235 | CARRIER IMMUNOGLOBULINS - Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide. | 2015-02-12 |
20150044236 | CARRIER IMMUNOGLOBULINS - Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide. | 2015-02-12 |
20150044237 | CHIMERIC MOLECULE INVOLVING OLIGOMERIZED FASL EXTRACELLULAR DOMAIN - New chimeric molecules involving in their structure, a combination of the extracellular domain (EC) of the FasL protein and a domain enabling oligomerisation of this Fas Ligand (FasL) EC domain, such as the Ig-like (so-called Ig in the following pages) domain of the gp190 receptor for the Leukemia Inhibitory Factor (LIF), or involving in their structure variants of the domains. Also, compositions including the chimeric molecule defined herein and the use of these chimeric molecules especially to trigger cytotoxic activity toward cells sensitive to FasL. | 2015-02-12 |
20150044238 | METHODS OF USING MONOMETHYLVALINE COMPOSITIONS HAVING PHENYLALANINE CARBOXY MODIFICATIONS AT THE C-TERMINUS - Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) having a carboxylic acid equivalent at the C-terminal phenylalanine were prepared and attached to ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand-drug conjugates were active in vitro and in vivo in inhibiting cell proliferation and are represented by the general structure of | 2015-02-12 |
20150044239 | Compositions and Methods for Diagnosing, Preventing and Treating Intracranial Aneurysms - The present invention relates to compositions and methods for diagnosing, preventing and treating intracranial aneurysm. | 2015-02-12 |
20150044240 | P53 VACCINES FOR THE TREATMENT OF CANCERS - The present invention relates to immunotherapy methods for treating hyperproliferative disease in humans, particularly to hyperproliferative disease that is refractory to therapy. More specifically, the invention is directed, in one embodiment, to methods for treating a subject with a hyperproliferative disease in which the expression of a self gene is upregulated in therapy-resistant hyperproliferative cells. In another embodiment, an adenoviral expression construct comprising a self gene under the control of a promoter operable in eukaryotic cells is administered to the therapy-resistant hyperproliferative cells. The present invention thus provides immunotherapies for treating therapy-resistant hyperproliferative disease by attenuating the natural immune system's CTL response against hyperproliferative cells or overexpressing mutant p53 antigens, for example. | 2015-02-12 |
20150044241 | CONTRACEPTIVE VACCINES FOR MAMMALS - The invention provides a contraceptive vaccine for a female recipient of a target species of mammals including a composition of at least one of a plurality of granulosa cells and a plurality of ovarian stromal cells in combination with an adjuvant; wherein the cells are grown from a tissue sample of the cells obtained from at least one female donor of the target species which is not the same individual as the female recipient. The invention also provides a method of producing the contraceptive vaccine as well as a method of treating a female recipient with the contraceptive vaccine to prevent pregnancy. | 2015-02-12 |
20150044242 | Adjuvant and Vaccine Compositions - Methods are provided for preparing and delivering an adjuvant for vaccines including lecithin, polymer and one or more additives. The polymer is preferably polyacrylic acid-based. The additive is preferably one or more of a glycoside and a sterol. The method of preparation includes hydrating lecithin and a polymer in saline or water and mixing the lecithin and polymer to form the adjuvant. Additives can be included prior to or after hydration of the lecithin and polymer. | 2015-02-12 |
20150044243 | MUCOSAL IMMUNIZATION TO PREVENT PRION INFECTION - Vaccines against prion disease eliciting a humoral immune response when administered mucosally are described. The vaccines comprise a prion protein, a prion protein fragment, or a non-amyloidogenic prion protein homolog and an adjuvant suitable for inducing a humoral immune response after mucosal administration. Suitable adjuvants include cholera toxin subunit B, heat-labile enterotoxin and aluminum hydroxide. Alternatively, the vaccine comprises a vector encoding a prion protein, fragment, or homolog in an attenuated | 2015-02-12 |
20150044244 | COMBINED FACILITATOR, ANTIGEN AND DNA VACCINE FOR PREVENTING AND TREATING AUTOIMMUNE DISEASES - The present invention relates to treating and preventing symptoms of an allergy, asthma, an autoimmune disease, and transplant rejection using a combination vaccine containing a vaccine facilitator comprising a Na/K pump inhibitor, an antigen and a DNA encoding the antigen. | 2015-02-12 |
20150044245 | PARTIAL MHC CONSTRUCTS AND METHODS OF USE - Disclosed herein are isolated major histocompatibility complex (MHC) class II α1 domain polypeptides and methods of use. In some embodiments, the isolated polypeptide comprises or consists of an MHC class II α1 domain polypeptide (or portion thereof) and does not include an MHC class II α2, β1, or β2 domain. The disclosed MHC class II α1 domain polypeptides are of use in treating or inhibiting disorders in a subject, such as inflammatory and/or autoimmune disorders. Also disclosed are methods of evaluating efficacy of treatment or optimizing treatment of a subject with a polypeptide including an MHC class II α1 domain polypeptide (or portion thereof) or a polypeptide including an MHC class II α1 domain and β1 domain (such as a β1α1 RTL). | 2015-02-12 |
20150044246 | METHOD FOR IDENTIFYING IMMUNOREACTIVE PEPTIDES - The invention relates to a method for identifying immunoreactive peptides. According to said method, a sample of tumorous and corresponding healthy tissue is first provided, the tumor-specific expression profile is subsequently determined and antigenic peptides are isolated from the tumorous tissue and analyzed. The respective data that has been obtained is then matched and peptides are identified on the basis of said data. | 2015-02-12 |
20150044247 | COMPUTATIONALLY OPTIMIZED BROADLY REACTIVE ANTIGENS FOR H3N2, H2N2, AND B INFLUENZA VIRUSES - Described herein is the generation of optimized H3N2, H2N2 and B influenza HA polypeptides for eliciting a broadly reactive immune response to influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on H3N2, H2N2 and B influenza isolates. Provided herein are optimized H3N2, H2N2 and B influenza HA polypeptides, and compositions, fusion proteins and VLPs comprising the HA polypeptides. Further provided are codon-optimized nucleic acid sequences encoding the HA polypeptides. Methods of eliciting an immune response against influenza virus in a subject are also provided by the present disclosure. | 2015-02-12 |
20150044248 | POLYPEPTIDES AND THEIR USE IN TREATING METAPNEUMOVIRUS (MPV) INFECTION - Polypeptides and compositions thereof are provided for treating or limiting metapneumovirus (MPV) infection, as well as methods for designing such polypeptides. In further aspects, methods of using said isolated polypeptides, VLPs or pharmaceutical compositions are provided, which include methods for treating a metapneumovirus (MPV) infection, methods for limiting development of an MPV infection, methods for generating an immune response in a subject, methods for monitoring an MPV-induced disease in a subject and/or monitoring response of the subject to immunization by an MPV vaccine, methods for detecting MPV binding antibodies, methods for producing MPV antibodies, and methods of preventing an MPV infection. | 2015-02-12 |
20150044249 | POLYVALENT CHIMERIC OSPC VACCINOGEN AND DIAGNOSTIC ANTIGEN - A chimeric polyvalent recombinant protein for use as a vaccine and diagnostic for Lyme disease is provided. The chimeric protein comprises epitopes of the loop 5 region and/or the alpha helix 5 region of outer surface protein C (OspC) types. The OspC types may be associated with mammalian | 2015-02-12 |
20150044250 | VACCINES AGAINST CLOSTRIDIUM DIFFICILE COMPRISING RECOMBINANT TOXINS - The present invention relates to recombinant | 2015-02-12 |
20150044251 | STABLE COMPOSITIONS FOR IMMUNISING AGAINST STAPHYLOCOCCUS AUREUS - Adding stabilizing additives to immunogenic compositions is effective in enhancing antigen stability. Suitable stabilizing additives include EDTA (ethylenediaminetetraacetic acid), sucrose, arginine, protease inhibitors, glycerol and/or citrate. | 2015-02-12 |
20150044252 | CORRELATION OF DISEASE ACTIVITY WITH CLONAL EXPANSIONS OF HUMAN PAPILLOMAVIRUS 16-SPECIFIC CD8+ T-CELLS IN PATIENTS WITH SEVERE EROSIVE ORAL LICHEN PLANUS - A massive clonal expansion of activated CD8 | 2015-02-12 |
20150044253 | IMMUNOGENIC COMPOSITION - The present application discloses an immunogenic composition comprising a Hib saccharide conjugate, at least one additional bacterial, for example | 2015-02-12 |
20150044254 | BIOCONJUGATES MADE FROM RECOMBINANT N-GLYCOSYLATED PROTEINS FROM PROCARYOTIC CELLS - The present invention is directed to a bioconjugate vaccine, such as an O1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, D/E-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O1-bioconjugate in a bioreactor comprising a number steps. | 2015-02-12 |
20150044255 | INFECTIOUS cDNA CLONE OF NORTH AMERICAN PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME (PRRS) VIRUS AND USES THEREOF - The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, wherein the polynucleotide molecule lacks at least one detectable antigenic epitope of North American PRRS virus. The invention also provides vaccines comprising genetically modified North American PRRS virus, RNA molecules, plasmids and viral vectors comprising the isolated polynucleotide molecules. Also provided are isolated polynucleotide molecules further comprising at least one nucleotide sequence that encodes a detectable heterologous antigenic epitope, and vaccines comprising North American PRRS virus, RNA molecules, plasmids and viral vectors comprising such isolated polynucleotide molecules. | 2015-02-12 |
20150044256 | Oral Vaccine For Borrelia - The present invention relates to vaccines for control of | 2015-02-12 |
20150044257 | BACULOVIRUS-BASED ENTEROVIRUS 71 VLP AS A VACCINE - An optimized baculovirus/insect cell-mediated system is provided for the production of enterovirus 71 virus-like particles to produce a vaccine against recent EV71 virus outbreaks. Co-expression of the viral capsid polyprotein P1 ORF derived from a fatal case in the Fuyang province of the People's Republic of China plus the 3 CD protease of EV71 prototype strain BrCr resulted in the formation of VLPs. The yields were increased by co-expression of both P1 and 3CD in separate transgene cassettes arranged in opposite orientation in a bicistronic baculovirus vector and by inserting the translational enhancing signal L21 in front of the capsid protein open reading frame. Faster transgene processing was achieved by using insect Sf21 cells instead of Sf9 cells. | 2015-02-12 |
20150044258 | PROCESS FOR T CELL EXPANSION - An in vitro expansion process for rapid expansion of antigen specific T cells, such as allogeneic antigen specific T cells comprising the steps culturing in a gas permeable vessel a population of PBMCs (such as allogeneic PBMCs) in the presence of antigen, for example a peptide or peptide mix relevant to a target antigen(s), in the presence of an exogenous cytokine characterized in that the expansion to provide the desired population of T cells is 14 days or less, for example 9, 10, 11 or 12 days, such as 10 days. The disclosure also extends to T cell populations generated by and obtained from the method and the use of same in therapy. | 2015-02-12 |
20150044259 | SCAFFOLD FOR ENHANCED NEURAL TISSUE REGENERATION - This application discloses a scaffold for promoting the growth of a nerve in a mammal while minimizing clumping, which comprises a support structure having an elongate opening formed therein and configured for placement around a damaged region of a nerve and a physiologically acceptable matrix composition in said opening, said matrix composition comprising a Poly-D Lysine (PDL) and a peptidoglycan, and Nerve Growth Factor (NGF). | 2015-02-12 |
20150044260 | NANOPARTICLE AGGREGATES CONTAINING OSTEOPONTIN AND CALCIUM- AND/OR STRONTIUM-CONTAINING PARTICLES - The present invention relates to nanoparticle aggregates comprising osteopontin (OPN) and one or more particles containing calcium and/or strontium and to their use for reducing or preventing biofilm growth or for removing biofilm. The invention furthermore relates to the use of the nanoparticle aggregates for treating, alleviating or preventing biofilm-related diseases. | 2015-02-12 |
20150044261 | Fatty Acid Conjugates of Quetiapine, Process for Making and Using the Same - The presently described technology provides a novel class of prodrugs of quetiapine that can be synthesized by chemically conjugating fatty acids to quetiapine. Pharmaceutical compositions and methods of synthesizing conjugates of the present technology are also provided. Methods of treating patients with the compositions of the present technology are also provided. | 2015-02-12 |
20150044262 | ENCAPSULATION OF PERFUMES - Core-shell capsules suitable for perfuming a consumer product comprising a polymeric shell surrounding and encapsulating a perfume-containing oil core, the mean diameter (D50) of which capsules is about 5 to 250 microns and which capsule is adapted to be ruptured to release perfume contained in the core under a rupture force of less than 2 milli Newtons (mN). | 2015-02-12 |
20150044263 | Kit comprising two separate compositions, notably for cosmetic application - A kit comprising two separate compositions (A) and (B). Composition (A) is an aqueous gel with a viscosity of less than 11 Pa·s and contains at least one capsule including: a liquid core with at least one active ingredient and a gelled envelope totally encapsulating the liquid core. The gelled envelope includes at least one polyelectrolyte in the gelled state. Composition (B) includes a depolymerizing agent. | 2015-02-12 |
20150044264 | Carbamates from Glycerine Carbonate for Pearlization - Alkyl and/or alkenyl glycerol carbamate prepared by reacting a carbonate selected from the group consisting of glycerol carbonate, diglycerol carbonate, polyglycerol carbonate and mixtures thereof, with an amine of the general formula (I): | 2015-02-12 |
20150044265 | COSMETIC COMPOSITION FOR IMPROVING SKIN ELASTICITY - Provided is a cosmetic composition for improving skin elasticity containing | 2015-02-12 |
20150044266 | Oral Compositions Comprising Propolis - Oral compositions are provided that comprise a propolis extract; a halogenated diphenyl ether non-ionic antibacterial agent; an anionic polymeric copolymer of methyl vinyl ether and maleic anhydride; and a source of fluoride ions. The oral composition can be in a form of a mouth rinse, a dentifrice, a confectionary, a medicament, or a film. Methods of making and using the oral compositions are also provided. | 2015-02-12 |
20150044267 | ADVANCED FABRIC TECHNOLOGY AND FILTERS - A filter material for entrapping particles and actively affecting the trapped particles within the filter. The fabric has a blend of hydrophilic superabsorbent fibers and non-superabsorbent hydrophilic fibers that is sufficiently porous as to allow gaseous flow through the fabric. The fabric having a thickness and the fabric has as a coating of a mixture of a chemically or physically active compound and a liquid carrier forming an active composition on both the outer surface of the hydrophilic superabsorbent fibers, and the hydrophilic superabsorbent fibers have a central volume also retaining the active composition. The central volume of the hydrophilic superabsorbent fibers acting as a reservoir for replacement of the active compound into the coating when concentration of active compounds in the coating are reduced to a concentration less than concentrations of the active compound within the central volume; and the liquid carrier is an aqueous liquid. | 2015-02-12 |
20150044268 | POLYMERIC MATERIALS FOR MEDICAL DEVICES - The present invention includes biocompatible polymeric coatings, membranes, matrices, and films to be used with implantable medical devices. Medical devices containing such materials applied to a surface thereof contain a film-forming fluorous homo-polymer or copolymer containing the polymerized residue of a fluorous moiety, wherein the relative amounts of the polymerized residues of one or more moieties are effective to provide the coating and films with properties effective for use in coating implantable med devices. | 2015-02-12 |
20150044269 | POLYMERIC MATERIALS FOR MEDICAL DEVICES - The present invention includes biocompatible polymeric coatings, membranes, matrices, and films to be used with implantable medical devices. Medical devices containing such materials applied to a surface thereof contain a film-forming fluorous homo-polymer or copolymer containing the polymerized residue of a fluorous moiety, wherein the relative amounts of the polymerized residues of one or more moieties are effective to provide the coating and films with properties effective for use in coating implantable med devices. | 2015-02-12 |
20150044270 | SUSTAINED DELIVERY OF THERAPEUTIC AGENTS TO AN EYE COMPARTMENT - Compositions and methods for treating eye disorders by administering a drug delivery system into an eye compartment of the patient, wherein the drug delivery system contains a particle containing a core; a coating associated with the particle, wherein the coating is covalently or non-covalently associated with the particle and presents a hydrophilic region to the environment around the particle; and a therapeutic agent are disclosed. The eye compartment can exhibit reduced inflammation or IOP after administration of the drug delivery systems to a patient than if a drug delivery system including an uncoated particle were administered to the patient. | 2015-02-12 |
20150044271 | SOLID DRUG IMPLANTS FOR INTRACOCHLEAR DELIVERY OF THERAPEUTICS FOR THE TREATMENT OF OTIC DISORDERS - The present invention provides for pharmaceutical preparations, devices, systems and methods for the treatment of otic diseases and conditions. In various embodiments, the preparations, devices, systems and methods enable sustained drug release for the treatment or prevention of hearing loss, infections, and other pathological conditions of cochlea and inner ear. | 2015-02-12 |
20150044272 | WOUND DRESSINGS, METHODS AND APPARATUS FOR MAKING SAME AND STORAGE AND USE THEREOF - Provided is a wound dressing prepared from whole blood that is clotted ex vivo to form a sheet of clotted blood that is applied onto the skin over a sight of skin injury. | 2015-02-12 |
20150044273 | MOLLUSCUM CONTAGIOSUM VIRAL FUSION PROTEIN TREATMENT FOR ATOPIC DERMATITIS DISEASES - Compositions, methods, and kits are provided for treating CCR8 mediated diseases with applicability to atopic dermatitis and potential applicability to asthma, prurigo nodularis, nummular dermatitis, neurodermatitis, and lichen simplex chronicus and some lymphomas, multiple sclerosis, acquired immunodeficiency disease, peritoneal adhesions, Kaposi's sarcoma and atherogenesis—the expression of all of which, at least in part, is mediated by cells expressing the chemokine receptor CCR8. The compositions include proteins and fusion proteins from Molluscum contagiosum Virus (MCV) or variants, analogs and derivatives thereof which exhibit inhibitory activity. Examples of such MCV proteins are MC148 fusion protein (MC148fp) identified as MC148P-TAT-6xHis (“6xHis” disclosed as SEQ ID NO: 11), and its variants, fragments, analogs and derivatives which possess inhibitory activity. The variants, fragments, analogs and derivatives of MC148p and of MC148fp may be less than 100% homologous to MCV proteins as long as they are sufficiently homologous that inhibitory activity is preserved. | 2015-02-12 |
20150044274 | BIPHASIC LIPID-VESICLE COMPOSITIONS AND METHODS FOR TREATING CERVICAL DYSPLASIA BY INTRAVAGINAL DELIVERY - This invention relates to biphasic lipid-vesicle compositions and methods for treating cervical displasia by intravaginal delivery. | 2015-02-12 |
20150044275 | BIPHASIC LIPID-VESICLE COMPOSITIONS AND METHODS FOR TREATING CERVICAL DYSPLASIA BY INTRAVAGINAL DELIVERY - This invention relates to biphasic lipid-vesicle compositions and methods for treating cervical displasia by intravaginal delivery. | 2015-02-12 |
20150044276 | BIPHASIC LIPID-VESICLE COMPOSITIONS AND METHODS FOR TREATING CERVICAL DYSPLASIA BY INTRAVAGINAL DELIVERY - This invention relates to biphasic lipid-vesicle compositions and methods for treating cervical displasia by intravaginal delivery. | 2015-02-12 |
20150044277 | MODIFIED POLYNUCLEOTIDES ENCODING CASPASE 3 - The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules. | 2015-02-12 |
20150044278 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS - The invention features methods of treating a proliferative disorder characterized by elevated Pin1 marker levels and/or reduced Pin1 Ser71 phosphorylation in a subject by administering a retinoic acid compound. Additionally, the invention features methods of treating proliferative disorders (e.g., proliferative disorders characterized by elevated Pin1 marker levels) by administering a retinoic acid compound in combination with another anti-proliferative compound. Finally, the invention also features methods including high-throughput screens for discovering and validating Pin1 inhibitors. | 2015-02-12 |
20150044279 | METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSE - Methods and compositions for enhancing the immune response to an IRM compound by depositing within a localized tissue region an IRM depot preparation that provides an extended residence time of active IRM within the localized tissue region. | 2015-02-12 |
20150044280 | TREATMENT METHODS USING ADENOVIRUS - The invention provides methods of reducing or decreasing a size of a tumor or eliminating a tumor or inhibiting, decreasing, or reducing neo-vascularization or angiogenesis in a tumor in a patient by administering an adenovirus comprising a nucleic acid construct comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter. Also provided is a homogeneous population of an adenovirus comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter and its uses thereof. | 2015-02-12 |
20150044281 | METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS AND OTHER DEMYELINATING DISORDERS - This invention provides compositions and methods for preventing multiple sclerosis or other demyelinating disorders, inhibiting multiple sclerosis or other demyelinating disorders, or prolonging remission from MS or other demyelinating disorders comprising administering to a subject a microparticle comprising a biodegradable material comprising at least one IL-10 coding sequence. | 2015-02-12 |
20150044282 | ABUSE RESISTANT FORMS OF IMMEDIATE RELEASE OXYCODONE, METHOD OF USE AND METHOD OF MAKING - An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided. | 2015-02-12 |